BetterHelp vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
World's largest online therapy platform, 30,000+ licensed therapists, Sunnyvale CA, owned by Teladoc Health. Consumer-focused text, phone, and video therapy.
About
BetterHelp is a Sunnyvale, California-based online therapy platform founded in 2013 and acquired by Teladoc Health in 2015. The platform is the world's largest online therapy service, with more than 30,000 licensed therapists and counselors available to members across the United States and internationally. BetterHelp is a direct-to-consumer service, allowing individuals to sign up, complete a brief matching questionnaire, and be paired with a therapist within days.\n\nMembers communicate with their therapist through multiple formats including text messaging, live chat, phone calls, and video sessions, offering a level of flexibility and asynchronous access that traditional therapy cannot match. Subscriptions are priced on a weekly or monthly basis with financial assistance available for lower-income members. BetterHelp has heavily invested in consumer brand awareness through podcast advertising and influencer partnerships, making it one of the most recognized names in consumer mental health.\n\nBetterHelp operates as part of Teladoc Health's mental health division alongside Teladoc's other behavioral health offerings, and the parent company's scale provides infrastructure and insurance relationship advantages. Despite facing regulatory scrutiny and advertiser criticism around messaging practices in 2022–2023, BetterHelp remains the dominant player in direct-to-consumer online therapy by volume of active clients and therapist network size.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.